NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension

@article{Keck2019NI956QGC006AP,
  title={NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension},
  author={M. Keck and Hugo de Almeida and D. Comp{\`e}re and N. Inguimbert and A. Flahault and F. Balavoine and B. Roques and C. Llorens-Cortes},
  journal={Hypertension},
  year={2019},
  volume={73},
  pages={1300–1307}
}
  • M. Keck, Hugo de Almeida, +5 authors C. Llorens-Cortes
  • Published 2019
  • Medicine
  • Hypertension
  • Brain renin-angiotensin system hyperactivity has been implicated in the development and maintenance of hypertension. [...] Key Result NI929 is 10× more efficient than EC33 at inhibiting recombinant mouse aminopeptidase A activity in vitro.Expand Abstract
    7 Citations

    References

    SHOWING 1-10 OF 44 REFERENCES
    Aminopeptidase A inhibitors as potential central antihypertensive agents.
    • 159
    • PDF
    Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension.
    • 99
    • PDF
    Synthesis and in vitro activities of new non-peptidic APA inhibitors.
    • N. Inguimbert, P. Coric, +5 authors B. Roques
    • Chemistry, Medicine
    • The journal of peptide research : official journal of the American Peptide Society
    • 2005
    • 19
    Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.
    • 280
    • PDF
    "Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes.
    • 127